Skip to main content
MedVellum
MCQsExamsAtlas
DashboardPricing
MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳MBBS / Core medicine✳Dermatology✳ICU Fellowship (CICM)✳Anaesthesia✳Emergency Medicine✳Psychiatry Fellowship✳Paediatrics Fellowship✳Physician Medicine✳MCQs✳SAQs✳Vivas✳OSCE✳Evidence-first✳

MedVellum.

The folio

Exam-exhaustive medical education across every specialty — evidence-graded topics, engraved plates, and practice in every written and oral format. Educational content only — not medical advice.

llms.txt · psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship
  • Paediatrics Fellowship
  • Physician Medicine

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Folio edition · Set in Instrument Serif & Archivo

Paeds Casesendocrinology-diabetes-and-growth

Paeds Cases · endocrinology-diabetes-and-growth

Counsel a family given a new diagnosis of glucocorticoid-induced osteoporosis — OSCE

OSCE communication and shared-planning station: breaking the news of glucocorticoid-induced osteoporosis in a steroid-treated boy with Duchenne muscular dystrophy who has a vertebral compression fracture, explaining the cause and the reassurance that the steroids are still needed, outlining the calcium and vitamin D preparation and the zoledronic acid treatment in plain language, and arranging bone surveillance.

osce communication and shared decision-making
On this page & tools

Target exams

MRCPCH ClinicalRACP DCERCPSC Pediatrics

Target exams

MRCPCH ClinicalRACP DCERCPSC Pediatrics
Prompt
The parents of a ten-year-old boy with Duchenne muscular dystrophy bring their son to clinic after three weeks of back pain; a lateral spine has shown a wedge compression fracture at T12, and the bone density is low. The boy has been on daily prednisolone for two years to preserve his muscle strength, and the parents are frightened — they worry the steroids caused the fracture and they do not know whether to stop them. Counsel them.

Communication framework

Establish what the parents already understand and fear. Ask the parents to recount what they have been told about the fracture and what they have read about the steroids, and acknowledge their fear directly. The worry that the prednisolone caused the fracture and the temptation to stop the steroids are the two you will spend the most time on, and you address them with the reassurance that the steroids are protecting the muscle and the heart and must not be stopped, and that the bone can be treated alongside the muscle. Do not correct them before you have heard them. [3] [1]

Explain the diagnosis in plain language. Your son's back pain comes from a small fracture in one of the bones of his spine, which we found on the side-view X-ray. We call this a vertebral compression fracture, and it happened because his bones have become thinner and more fragile than they should be for his age. This is called osteoporosis, and in children it means the combination of fragile bones and a fracture. In your son it has happened for two reasons working together: the prednisolone that is protecting his muscle can thin the bones over time, and because he is moving less, his bones are not getting the weight-bearing they need to stay strong. [1] [3]

Address the steroid fear directly. The prednisolone did play a part in thinning the bones, and I will not pretend it did not — but it is also the medicine that is keeping your son walking and protecting his heart, and stopping it suddenly would be dangerous and would not fix the bone. So we do not stop the steroids. Instead, we treat the bone with a medicine that strengthens it, and we make sure he has enough calcium and vitamin D, and we keep him as active and weight-bearing as he safely can be. The two treatments work side by side. [3] [4]

The treatment and the monitoring plan

Explain the calcium and vitamin D preparation and the bisphosphonate simply. Before we start the bone medicine, we make sure your son's calcium and vitamin D levels are good, because the medicine can briefly lower the calcium in the blood in the first day or two and we want to avoid that. The bone medicine itself is called zoledronic acid, and it is given through a drip into a vein about once every several months as a day visit. It works by slowing down the cells that take bone away, so the cells that build bone can catch up and the spine and other bones get stronger. It has been tested properly in children on steroids and it works. [2] [4]

Explain the first-dose reaction and the monitoring. On the first dose, your son may feel flu-like for a day or two — a fever and aching — and we manage that with paracetamol and fluids, and it is much less common after the second dose. We then check the bloods and repeat the side-view X-ray of the spine and the bone-density scan at intervals to watch the bones get stronger and the fractured vertebra remodel. Because your son is growing, the bones can recover a great deal, and our aim is to protect his skeleton all the way through his teenage years so that he carries the strongest bones he can into adult life. [2] [1]

Close with shared planning and safety-netting

Agree a clear, written plan and a safety net. Give the parents the date of the infusion, the calcium and vitamin D instructions, the next appointment for the bone check, and the number to call if the back pain worsens or new pain appears. Confirm their understanding by asking them to repeat the plan, and offer a link to a reliable family resource on bone health in Duchenne muscular dystrophy. Reassure them that the bone programme runs alongside the muscle and heart care, that the team coordinates all of it, and that the fracture is a setback that the treatment can address, not a reason to stop the medicine that is protecting their son. [3] [4]

References

  1. [1]Bishop N, Arundel P, Clark E, et al. Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions. J Clin Densitom, 2014.PMID 24631254
  2. [2]Ward LM, Choudhury A, Alos N, et al. Zoledronic Acid vs Placebo in Pediatric Glucocorticoid-induced Osteoporosis: A Randomized, Double-blind, Phase 3 Trial. J Clin Endocrinol Metab, 2021.PMID 34228102
  3. [3]Ward LM, Weber DR, Wong SC, et al. A Parent Project Muscular Dystrophy-sponsored International Workshop Report on Endocrine and Bone Issues in Patients with Duchenne Muscular Dystrophy: An Ever-changing Landscape. J Neuromuscul Dis, 2025.PMID 39973454
  4. [4]Simm PJ, Biggin A, Zacharin MR, et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health, 2018.PMID 29504223